Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients
Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
Company Research
Source: Business Wire
CHARLOTTE, N.C. & CARDIFF, United Kingdom--(BUSINESS WIRE)--Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products for gastrointestinal cancers, have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis (FAP) through an Early Access / Named Patient Program.FAP is characterized by a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option, and surgical resection remains the standard of care.eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor involved in cellular metabolism, growth, and proliferation and activated during tumorigenesis. mTOR has been shown to be over-expressed in FAP polyps, supporting the rationale for its use in treatment.Through this collaboration, Tanne
Show less
Read more
Impact Snapshot
Event Time:
BDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDRX alerts
High impacting Biodexa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BDRX
News
- Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial SuppliesGlobeNewswire
- BDRX: Initiating Coverage of Biodexa Pharmaceuticals; A Deep Value Oncology Platform Built Around Two High-Conviction Areas [Yahoo! Finance]Yahoo! Finance
- Biodexa Pharmaceuticals (BDRX) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BDRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fromMarketBeat
- Preliminary Results for the Year Ended 31 December 2025 [Yahoo! Finance]Yahoo! Finance
- Preliminary Results for the Year Ended 31 December 2025GlobeNewswire
BDRX
Sec Filings
- 3/31/26 - Form EFFECT
- 3/31/26 - Form EFFECT
- 3/31/26 - Form EFFECT
- BDRX's page on the SEC website